Cooley advised the placement agents to Korsana Biosciences, a privately held biotechnology company discovering and developing novel therapies to reduce the burden of neurodegenerative diseases, in connection with an approximately $380 million private placement concurrent with its merger with Cyclerion Therapeutics. The syndicate of investors is led by Fairmount and Venrock Healthcare Capital Partners, with participation from General Atlantic, TCGX, Forbion, Wellington Management, Commodore Capital, RA Capital Management, RTW Investments, Vivo Capital, Janus Henderson Investors, Foresite Capital, J.P. Morgan Life Sciences Private Capital, SR One, Sanofi Ventures, Kalehua Capital, Spruce Street Capital and other leading investment management firms.